US hospital says “no” to spiralling price of oncology drugs

In an op-ed in the New York Times on 14 September 2012, Memorial Sloan-Kettering Cancer Center published the rationale for their decision not to give Sanofi and Regeneron’s new drug, Zaltrap, to their patients with colorectal cancer. The authors cite … Continue reading